J, C., RE, D., MA, M., A, S., E, M., E, S., . . . NM, B. (2024). Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip. Antimicrobial agents and chemotherapy, 68(8), e0065524. https://doi.org/10.1128/aac.00655-24
Chicago Style (17th ed.) CitationJ, Conway, et al. "Phase 1 Study of the Pharmacokinetics and Clinical Proof-of-concept Activity of a Biofilm-disrupting Human Monoclonal Antibody in Patients with Chronic Prosthetic Joint Infection of the Knee or Hip." Antimicrobial Agents and Chemotherapy 68, no. 8 (2024): e0065524. https://doi.org/10.1128/aac.00655-24.
MLA (9th ed.) CitationJ, Conway, et al. "Phase 1 Study of the Pharmacokinetics and Clinical Proof-of-concept Activity of a Biofilm-disrupting Human Monoclonal Antibody in Patients with Chronic Prosthetic Joint Infection of the Knee or Hip." Antimicrobial Agents and Chemotherapy, vol. 68, no. 8, 2024, p. e0065524, https://doi.org/10.1128/aac.00655-24.
